AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary OntosightⓇ Explore platform. The recognition comes in the category of Artificial Intelligence & User Experience. The finalists of the Edison Awards were announced on February 11th, 2020.
OntosightⓇ Explore is a specialized life science based AI-based platform for exploring and identifying non-obvious connections between diseases, pathways, proteins/targets, and drugs. It helps to capture insights and visualize a comprehensive network of biological knowledge to better understand disease pathways and uncover novel mechanisms of action (MoA.) This expanded knowledge can drive clinical development and help to bring life saving drugs to patients.
OntosightⓇ Explore helps a researcher understand the interconnectedness of biological systems with regard to their search term, which can be a gene, target/protein, pathway, or disease. Through aggregation of all available information, it identifies all the diseases including their associated pathways and molecular interactions which are responsible for its origin and severity. Target identification is a crucial step in drug discovery as it opens a door for new therapeutic development. Researchers can leverage OntosightⓇ Explore to identify all known and potential pathways through which a treatment breakthrough can be achieved.
Featured News
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trials BOSTON and DURHAM, N.C. and ESCHBORN, Germany,…